Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 40 of the 56 sources its claims cite were checked for support.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have been approved to target obesity-related heart failure with preserved ejection fraction. METHODS: We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The dual primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in the 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001). The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001). In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95% CI, 1.37 to 2.15; P<0.001). The mean percentage change in the CRP level was -43.5% with semaglutide and -7.3% with placebo (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). Serious adverse events were reported in 35 participants (13.3%) in the semaglutide group and 71 (26.7%) in the placebo group. CONCLUSIONS: In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Overview
CoChat Summary
TL;DR
In STEP-HFpEF, once-weekly semaglutide 2.4 mg versus placebo in patients with heart failure with preserved ejection fraction and obesity improved heart failure symptoms/physical limitations, body weight, exercise function, a hierarchical composite outcome, and CRP over 52 weeks. Semaglutide also had fewer serious adverse events than placebo.
Key findings
- Dual primary end points: mean KCCQ-CSS change was 16.6 points with semaglutide vs 8.7 with placebo (estimated difference, 7.8 points; 95% CI, 4.8 to 10.9; P<0.001), and mean body weight changed by -13.3% vs -2.6% (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).
- Confirmatory secondary end points: 6-minute walk distance changed by 21.5 m vs 1.2 m (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001); hierarchical composite win ratio was 1.72 (95% CI, 1.37 to 2.15; P<0.001); CRP changed by -43.5% vs -7.3% (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001).
- Safety: serious adverse events occurred in 35 participants (13.3%) with semaglutide vs 71 (26.7%) with placebo (P<0.001), driven mainly by fewer cardiac disorder events (7 [2.7%] vs 30 [11.3%]; P<0.001); discontinuation due to any adverse event occurred in 35 vs 14 participants, predominantly gastrointestinal events.
- Exploratory: adjudicated heart failure hospitalization or urgent visit occurred in 1 semaglutide participant vs 12 placebo participants (hazard ratio, 0.08; 95% CI, 0.00 to 0.42).
Methods
- Randomized, double-blind, placebo-controlled trial at 96 sites in 13 countries; 529 participants with HFpEF, BMI ≥30, LVEF ≥45%, NYHA class II–IV, KCCQ-CSS <90, and 6-minute walk distance ≥100 m were assigned 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks plus 5-week follow-up.
- Dual primary end points were change in KCCQ-CSS and percentage change in body weight at week 52; confirmatory secondary end points included 6-minute walk distance, a hierarchical composite (death, heart failure events, KCCQ-CSS and 6-minute walk differences), and CRP.
- Efficacy was analyzed in the full analysis population using the treatment policy estimand; continuous end points used ANCOVA, the hierarchical composite used a win-ratio approach, and safety was analyzed in the as-treated safety population.
Limitations
- Stated in the paper: the number of non-White participants was low, which may limit generalizability; the trial was not adequately powered for clinical events such as heart failure hospitalizations/urgent visits; follow-up was limited to 1 year; specific glycated hemoglobin data were not collected beyond excluding diabetes; and SGLT2 inhibitor use was low.
- Evident from the text: the trial population was 95.8% White, median age 69 years, all with BMI ≥30, and patients with diabetes were excluded, so findings may not generalize to more diverse, younger, non-obese, or diabetes populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 90 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that obesity and excess adiposity are not simply coexisting conditions but may play a role in the development and progression of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Background calls obesity a risk factor for incident heart failure, and the Discussion links severe obesity to more adverse outcomes and hospitalizations among patients who already have HFPEF. These findings support the hedged suggestion that obesity may matter beyond coexistence, but the paper does not establish a role for excess adiposity specifically in the development or progression of HFPEF; its HFPEF analysis concerns BMI and outcomes. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. source
The Discussion (page not provided) states that increased adiposity promotes conditions that contribute to HFpEF pathophysiology. The Conclusions (page not provided) add that adipose deposition may have adverse consequences for HFpEF. Together, these support the citing sentence’s hedged claim that adiposity may play a role rather than merely coexist with the disease. (LLM, conf=0.88)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The main text explicitly says that excess adipose tissue likely plays a pivotal role in the development and progression of HFpEF. It also describes evidence linking adiposity to incident HFpEF and adverse outcomes in established HFpEF. This supports the citing sentence’s hedged claim that obesity and excess adiposity may contribute rather than merely coexist. (LLM, conf=0.94)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5 describes obesity-related changes that can lead to HFpEF. Section 5.8.1 links visceral adiposity to the risk of developing HFpEF and reports that central adiposity is associated with worse outcomes in patients who have it. Together, these passages support the hedged claim that excess adiposity may contribute to development and progression. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that adipose tissue may play a pivotal role in the development, progression, and adverse outcomes of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a U-shaped association between BMI and adverse outcomes in patients with HFpEF, and the paper describes obesity as a risk factor for developing heart failure generally. It does not establish a role for adipose tissue in HFpEF progression or specifically in its development; BMI is not a direct measure of adipose-tissue activity. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Partly supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says increased adiposity contributes to HFpEF pathophysiology and links abdominal fat to impaired exercise tolerance in older obese patients. This supports a possible role for adipose tissue, but the paper does not establish its role in HFpEF progression or in adverse clinical outcomes. (LLM, conf=0.85)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The paper’s main text explicitly says that excess adipose tissue likely plays a pivotal role in HFpEF development, progression, and adverse outcomes. It also identifies visceral adipose tissue as especially important in metabolic/obese HFpEF. (LLM, conf=0.95)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5.8.1 (page not provided) describes a pivotal role for visceral adipose tissue in obese HFpEF, linking it to both incident HFpEF risk and worse outcomes. Section 5.3 (page not provided) describes mechanisms by which epicardial adipose tissue may impair cardiac function and reports associations with greater disease severity and hospitalization or death. Together, these passages support the claim’s hedged wording. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Even when patients have well compensated heart failure with preserved ejection fraction and are in stable condition, they have markedly impaired objectively measured physical function. 34”
What the sources say
- Partly supportedcites [34] 34. Pandey A, Shah SJ, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78: 1166-87. sourceExperimental — accuracy not yet measured
In ‘EI: A Key Manifestation of HFpEF’ (page unavailable), the review reports that objectively measured peak oxygen uptake is, on average, 35% lower in patients with HFpEF than in matched healthy controls. This supports marked impairment, but the passage does not establish that the patients were well-compensated and clinically stable. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our findings of substantial reductions in symptoms and physical limitations and improvements in exercise function that parallel a greater degree of weight loss with semaglutide than with placebo may offer insights into the long-standing controversy surrounding weight (and weight loss) in persons with heart failure. 8”
What the sources say
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“previous global clinical trial programs of agents such as SGLT2 inhibitors, sacubitrilvalsartan, and spironolactone for heart failure with preserved ejection fraction showed only modest changes in KCCQ scores (ranging from 0.5 to 2.3 points). 31-33”
What the sources say
- Partly supportedcites [31] 31. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 2022; 145: 184-93. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports modest KCCQ improvements in the TOPCAT spironolactone and PARAGON-HF sacubitril/valsartan trials, while the Results report modest improvements with the SGLT2 inhibitor empagliflozin. These passages support the overall characterization, but they do not establish the stated range of 0.5 to 2.3 points. (LLM, conf=0.86)
- Partly supportedcites [32] 32. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status inpatients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2023; 81: 460-73. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes the KCCQ benefit with dapagliflozin in DELIVER as modestly higher than that with empagliflozin in EMPEROR-PRESERVED, and mentions the sacubitril-valsartan PARAGON-HF trial. It does not establish the claimed 0.5–2.3-point range across those trials or report a corresponding spironolactone result. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [33] 33. Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2016; 9(3): e001937. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims · 1 with their cited sources checked
Create a free account to see all 113 claims and every source verdict.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and there is evidence that semaglutide 2.4 mg improves heart failure with preserved ejection fraction in individuals without diabetes by a potentially direct or indirect effect on epicardial adipose tissue (Kosiborod et al, 2023;Myasoedova et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Kosiborod et al, 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with HFpEF and obesity (with and without diabetes), semaglutide 2.4 mg once weekly for 52 weeks improved symptoms, physical function, exercise function and bodyweight compared to placebo (STEP HFpEF and STEP HFpEF DM clinical trials) [59,91].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the STEP-HFpEF trial, semaglutide treatment in patients with obesity-related HFpEF led to significant improvements in the 6-min walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), despite concurrent losses in lean mass [38].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“weight-loss interventions (eg, gastric bypass surgery and glucagon-like peptide-1 receptor agonists) can reduce the risk of incident HF and improve symptoms in patients with established HFpEF.16–20”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
39 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationO'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Self-citationHeart Failure With Preserved, Borderline, and Reduced Ejection Fraction
Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.074 · Cited by 1,110
Epidemiology of Heart Failure: A Contemporary Perspective
Roger, V. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318172 · Cited by 946
Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Self-citationBordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Self-citation
Cited by
Items 101–200 of 1,639
Saglietto, A., Falasconi, G., Penela, D., Francia, P., Sau, A., Ng, F. S., Dusi, V., Castagno, D., Gaïta, F., Berruezo, A., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14292 · Cited by 76
Sarcopenic Obesity and Cardiovascular Disease: An Overlooked but High-Risk Syndrome
Mirzai, S., Carbone, S., Batsis, J. A., Kritchevsky, S. B., Kitzman, D. W., & Shapiro, M. D. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00571-2 · Cited by 76
Self-citationMericskay, M., Zuurbier, C. J., Heather, L. C., Karlstaedt, A., Inserte, J., Bertrand, L., Kararigas, G., Ruiz‐Meana, M., Maack, C., & Schiattarella, G. G. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01166-7 · Cited by 80
“Emerging evidence suggests that interventions targeting obesity and its metabolic consequences, such as weight reduction, insulin sensitizers and lipid-modulating therapies, will shape the future management of patients with cardiometabolic HFpEF 17,18 .”
Schou, M., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Verma, S., Patel, S., Chinnakondepalli, K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.038 · Cited by 70
Self-citationHeather, L. C., Gopal, K., Srnic, N., & Ussher, J. R. (2024) · Diabetes · doi:10.2337/dbi23-0019 · Cited by 69
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1379189 · Cited by 57
“Within the latter, a study speci fi cally including patients with heart failure with preserved ejection fraction is highlighted (35).”
BackgroundMethodInfluentialRivera, F. B., Lumbang, G. N. O., Gaid, D. R. M., Cruz, L. L. A., Magalong, J. V., Bantayan, N. R. B., Lara‐Breitinger, K. M., Gulati, M., & Bakris, G. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15529 · Cited by 57
García‐Vega, D., Sánchez-López, D., Rodríguez-Carnero, G., Villar‐Taibo, R., Viñuela, J. E., Lestegás-Soto, A., Seoane‐Blanco, A., Moure‐González, M., Bravo, S. B., Fernández, Á. L., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02096-9 · Cited by 72
Gilden, A. H., Catenacci, V. A., & Taormina, J. M. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202405210 · Cited by 60
Old, V. J., Davies, M. J., Papamargaritis, D., Choudhary, P., & Watson, E. L. (2025) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13677 · Cited by 55
Self-citationPharmacotherapy for obesity: moving towards efficacy improvement
Coutinho, W. F., & Halpern, B. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01233-4 · Cited by 70
“Another phase-3 trial evaluated the effect on weight loss and heart failure-specific symptoms of semaglu-tide 2.4 mg versus placebo in 529 adults with obesity and heart failure with preserved ejection fraction [108].”
BackgroundInfluentialMyocardial fibrosis from the perspective of the extracellular matrix: Mechanisms to clinical impact
Lunde, I. G., Rypdal, K. B., Linthout, S. V., Díez, J., & González, A. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.08.008 · Cited by 68
Bonfioli, G. B., Rodella, L., Metra, M., & Vizzardi, E. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10450-6 · Cited by 65
Ebrahimi, P., Batlle, J. C., Ayati, A., Maqsood, M. H., Long, C., Tarabanis, C., McGowan, N., Liebers, D. T., Laynor, G., Hosseini, K., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0091 · Cited by 51
Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management
Gallo, G., Desideri, G., & Savoia, C. (2024) · Nutrients · doi:10.3390/nu16162781 · Cited by 74
“However, a trend toward reducing these outcomes has been re-ported [112].”
BackgroundCimino, G., Vaduganathan, M., Lombardi, C., Pagnesi, M., Vizzardi, E., Tomasoni, D., Adamo, M., Metra, M., & Inciardi, R. M. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14560 · Cited by 67
“HF events were reduced in diabetic patients with no HF at baseline whereas they were generally not changed in the RCTs enrolling patients with HF. 81 With respect of the results in patients with HFrEF, liraglutide had no effect on LV ejection fraction (LVEF), increased heart rate, and increased serious cardiac events…”
BackgroundResultInfluentialStolfo, D., Iacoviello, M., Chioncel, O. D., Anker, M. S., Bayés‐Genís, A., Braunschweig, F., Cannata, A. N., Hadidi, S. E., Filippatos, G., Jhund, P. S., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3642 · Cited by 62
“26–28 Chronic kidney disease is a frequent real or perceived barrier to the optimization of HF GDMT, but GDMT has evidence of benefit and safety also in patients with chronic kidney disease up to stage 3b/4, 29 and therefore during the processes of therapeutic revision and reassessment of…”
Mechano-energetic uncoupling in heart failure
Aksentijević, D., Sedej, S., Fauconnier, J., Paillard, M., Abdellatif, M., Streckfuß‐Bömeke, K., Ventura‐Clapier, R., van der Velden, J., de Boer, R. A., Bertero, E., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01167-6 · Cited by 60
“In patients with HFpEF and obesity, the GLP1 receptor agonist semaglutide reduced body weight, improved quality of life and lowered plasma NT-proBNP and C-reactive protein concentrations 23,24 .”
Forny Germano, L., Koehler, J. A., Baggio, L. L., Cui, F., Wong, C. K., Rittig, N., Cao, X., Matthews, D., & Drucker, D. J. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102019 · Cited by 50
“GLP-1RAs also improve functional outcomes in subjects with heart failure and preserved ejection fraction [5].”
Hoeper, M. M., Oerke, B., Wißmüller, M., Leuchte, H. H., Opitz, C. F., Halank, M., Seyfarth, H.-J., Baldus, S. E., Bauersachs, J. K., Böhm, M., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069340 · Cited by 54
Muse, E. D., & Topol, E. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.02.002 · Cited by 50
Verma, S., Butler, J., Borlaug, B. A., Davies, M. J., Kitzman, D. W., Petrie, M. C., Shah, S. J., Jensen, T. J., Rasmussen, S., Rönnbäck, C., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.023 · Cited by 52
Self-citationPacker, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.009 · Cited by 49
Self-citationDiscovery of Titin and Its Role in Heart Function and Disease
Granzier, H. L. M., & Labeit, S. (2025) · Circulation Research · doi:10.1161/circresaha.124.323051 · Cited by 57
Silverii, G. A., Pala, L., Cresci, B., & Mannucci, E. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16076 · Cited by 49
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction
Butt, J. H., Henderson, A. D., Jhund, P. S., Claggett, B. L., Desai, A. S., Lay‐Flurrie, J., Viswanathan, P., Lage, A. Z., Scheerer, M. F., Lam, C. S. P., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.111 · Cited by 56
Self-citationNdumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 153
Incretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
Associations between Class I, II, or III Obesity and Health Outcomes
Yao, Z., Tchang, B. G., Albert, M. H., Blumenthal, R. S., Nasir, K., & Blaha, M. J. (2025) · NEJM Evidence · doi:10.1056/evidoa2400229 · Cited by 64
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
Patel, R., Sharma, A., Prasad, A., & Bansal, S. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100705 · Cited by 65
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Khera, R., Aminorroaya, A., Dhingra, L. S., Thangaraj, P. M., Pedroso Camargos, A., Bu, F., Ding, X., Nishimura, A., Anand, T. V., Arshad, F., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.069 · Cited by 47
Ferreira, J. P., Claggett, B. L., Liu, J., Sharma, A., Desai, A. S., Anand, I. S., O’Meara, E., Rouleau, J. L., de Denus, S., Pitt, B., et al. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.131818 · Cited by 58
Khera, R., Aminorroaya, A., Dhingra, L. S., Thangaraj, P. M., Camargos, A. P., Bu, F., Ding, X., Nishimura, A., Anand, T. V., Arshad, F., et al. (2024) · doi:10.1101/2024.02.05.24302354 · Cited by 46
“62 Our study favors the continued evaluation of GLP1-RA as a therapy to reduce HF risk and improve outcomes of those with HF. 63,64 There are limitations that merit consideration.”
Gasiorek, A., Heydorn, A., Gabery, S., Hjerpsted, J. B., Kirkeby, K., Kruse, T., Petersen, S. B., Toubro, S., Vegge, A., & Key, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01176-6 · Cited by 46
Savarese, G., Schiattarella, G. G., Lindberg, F., Anker, M. S., Bayés‐Genís, A., Bäck, M., Braunschweig, F., Bucciarelli‐Ducci, C., Butler, J., Cannata, A. N., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3676 · Cited by 57
Self-citationJCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 67
Sawami, K., Tanaka, A., & Node, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02500-y · Cited by 44
“The effect of semaglutide subcutaneous injection at 2.4 mg per week in patients with HFpEF and obesity (BMI ≥ 30 kg/m 2 ) but without diabetes was tested in STEP-HFpEF [29].”
InfluentialMyocardial ultrastructure of human heart failure with preserved ejection fraction
Meddeb, M., Koleini, N., Binek, A., Keykhaei, M., Darehgazani, R., Kwon, S., Aboaf, C. C., Margulies, K. B., Bedi, K., Lehar, M., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00516-x · Cited by 44
“In 2023, weight loss afforded by glucagon-like peptide-1 therapy was found to benefit HFpEF symptoms in humans 13 , further highlighting the importance of obesity and myocardial metabolism 14 .”
Self-citationEffects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study
Ditzenberger, G. L., Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Moser, C., Belaunzaran-Zamudio, P. F., Brown, T. T., Corey, K., Landay, A. L., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciae384 · Cited by 44
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 57
Sattar, N. A., & Lee, M. M. Y. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00363-2 · Cited by 58
Contributions of Inflammation to Cardiometabolic Heart Failure with Preserved Ejection Fraction
Thorp, E. B., & Filipp, M. E. (2024) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023405 · Cited by 51
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
Hu, E.-H., Tsai, M.-L., Lin, Y., Chou, T.-S., & Chen, T.-H. (2024) · Medicina · doi:10.3390/medicina60030357 · Cited by 43
“Moreover, the STEP-HFpEF trial indicated that semaglutide improved physical functioning (as assessed by 6-min walk distance), preserved HFpEF, and reduced weight in patients with HF and obesity [58].”
BackgroundTrends in Heart Failure Mortality in Sweden Between 1997 and 2022
Lindberg, F., Benson, L., Dahlström, U., Lund, L. H., & Savarese, G. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3506 · Cited by 53
“…on intravenous iron, 36 non-steroidal mineralocorticoid receptor antagonists (MRA), 37 and glucagon-like peptide-1 receptor agonists may suggest, 38 tailored therapies targeting non-cardiac comorbidities may have potential to improve health status and potentially cardiovascular outcomes in…”
Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF
Luo, L., Zuo, Y., & Dai, L. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02707-7 · Cited by 56
“Glucagon-like peptide-1 receptor agonist (GLP1-RA) In the STEP-HFpEF trial, the GLP1-RA semaglutide alleviated symptoms and physical limitations, improved exercise function, and promoted weight loss in HFpEF with obesity [137].”
Chang, M. G., Ripoll, J. G., Lopez, E., Krishnan, K., & Bittner, E. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216336 · Cited by 43
Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity
Hwang, J. H., Laiteerapong, N., Huang, E. S., Mozaffarian, D., Fendrick, A. M., & Kim, D. D. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2025.0905 · Cited by 43
Psaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 51
“31 FIGURE 1 Global trends in obesity, T2DM and cardiovascular disease.”
The double burden: type 1 diabetes and heart failure—a comprehensive review
Julián, M. T., de, A. P.-M., Julve, J., & Alonso, N. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02136-y · Cited by 55
“Recently, treatment with a GLP1-RA (semaglutide) was associated with improved symptoms and exercise capacity in patients with HFpEF and obesity [137].”
BackgroundO'Keefe, J. H., Franco, W. G., & O'Keefe, E. L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.12.010 · Cited by 42
Ottosen, C. I., Nadruz, W., Inciardi, R. M., Johansen, N. D., Fudim, M., & Biering‐Sørensen, T. (2024) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeae178 · Cited by 54
Cesaro, A., Pastori, D., Acerbo, V., Biccirè, F. G., Golino, M., Panico, D., Prati, F., Abbate, A., Lip, G. Y. H., & Calabrò, P. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf257 · Cited by 56
Kosyakovsky, L. B., Liu, E. E., Wang, J. K., Myers, L., Parekh, J. K., Knauss, H., Lewis, G. D., Malhotra, R., Nayor, M., Robbins, J. M., et al. (2024) · Circulation: Heart Failure · doi:10.1161/circheartfailure.123.011366 · Cited by 43
“31,32 The role of these evolving therapies among those without evidence of rest congestion or in the prevention of HFpEF remains to be defined.”
BackgroundTheodorakis, N., & Nikolaou, M. (2025) · Biomedicines · doi:10.3390/biomedicines13010135 · Cited by 50
“Subgroup analyses demonstrated consistent benefits across age, sex, and baseline NYHA classes [46].”
Reddy, Y. N. V., Frantz, R. P., Hemnes, A. R., Hassoun, P. M., Horn, E. M., Leopold, J. A., Rischard, F. P., Rosenzweig, E. B., Hill, N. S., ERZURUM, S. C., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.530 · Cited by 45
Self-citationTada, A., Burkhoff, D., Naser, J. A., Harada, T., Pourmussa, B., Reddy, Y. N. V., Jensen, M. D., Carter, R. E., Demmer, R. T., Testani, J. M., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.068788 · Cited by 42
Self-citationMentias, A., Desai, M. Y., Aminian, A., Patel, K. V., Keshvani, N., Verma, S., Cho, L., Jacob, M., Alvarez, P., Lincoff, A. M., et al. (2024) · Circulation: Heart Failure · doi:10.1161/circheartfailure.122.010453 · Cited by 40
“47 Furthermore, the SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity) trial results demonstrate a significant reduction in the risk of major adverse cardiovascular events with the use of semaglutide among individuals with obesity and CVD (4274 of 17 605…”
BackgroundSelf-citationSemaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 55
“In addition, these studies showed that 2.4 mg of subcutaneous SMG (Wegovy ® ) improved cardiac remodeling, reduced cardiovascular symptoms and inflammation, and decreased physical limitations [50–52, 133 –135”
InfluentialLassen, M. C. H., Johansen, N. D., Modin, D., Catarig, A., Vistisen, B. K., Amadid, H., Zimmermann, E., Gislason, G., & Biering‐Sørensen, T. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15872 · Cited by 40
Madsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“%) was assessed in a trial including 529 participants with a median BMI of 37 kg/m 2 [46,47].”
Gregson, J., Taylor, D., Owen, R., Collier, T. J., Cohen, D. J., & Pocock, S. (2025) · Circulation · doi:10.1161/circulationaha.124.070251 · Cited by 48
“30 In general, such stratified analyses slightly increase statistical power when the stratifying variables are strongly prognostic for the outcome.”
Gorica, E., Geiger, M. A., Venanzio, L. D., Atzemian, N., Kleeberger, J., Grigorian, D., Mongelli, A., Veseli, B. E., Mohammed, S. A., Ruschitzka, F. T., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02774-w · Cited by 55
Edmonston, D. L., Mulder, H. S., Lydon, E. J., Chiswell, K., Lampron, Z. M., Shay, C. M., Marsolo, K. A., Shah, R. C., Jones, W. S., Gordon, H. S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.016 · Cited by 47
Self-citationSattar, N. A., Butler, J., Lee, M. M. Y., Harrington, J., Sharma, A., Zannad, F. M., Filippatos, G. S., Verma, S., Januzzi, J. L., Ferreira, J. P., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3221 · Cited by 44
Self-citationDronkers, J., van Veldhuisen, D. J., van der Meer, P., & Meems, L. M. G. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.016 · Cited by 48
Abdin, A., Böhm, M., Shahim, B., Karlström, P., Kulenthiran, S., Skouri, H. N., & Lund, L. H. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132304 · Cited by 53
Zhang, Z., Wang, C., Tu, T., Lin, Q., Zhou, J., Huang, Y., Wu, K., Zhang, Z., Zuo, W., Liu, N., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00646-4 · Cited by 43
“The STEP-HFpEF trial demonstrated that semaglutide significantly ameliorated weight and HF symptoms and reduced HF events in obese patients with HFpEF [114].”
BackgroundObesity in the Asia-Pacific Region: Current Perspectives
Lui, D. T. W., Ako, J., Dalal, J. J., Fong, A. Y. Y., Fujino, M., Horton, A., Krittayaphong, R., Almahmeed, W. A., Matthias, A. T., Nelson, A. J., et al. (2024) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2023.68 · Cited by 49
“73”
Obesity and Weight Loss Strategies for Patients With Heart Failure
Vest, A. R., Schauer, P. R., Rodgers, J. E., Sanderson, E., LaChute, C., Seltz, J., Lavie, C. J., Mandras, S. A., Tang, W. H. W., & daSilva‐deAbreu, A. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.06.006 · Cited by 47
Hosseinpour, A., Sood, A., Kamalpour, J., Zandi, E., Pakmehr, S., Hosseinpour, H., Sood, A., Agrawal, A., & Gupta, R. (2024) · Clinical Cardiology · doi:10.1002/clc.24314 · Cited by 40
Wharton, S., le Roux, C. W., Kosiborod, M., Platz, E., Brueckmann, M., Jastreboff, A. M., Hussain, S. A., Pedersen, S. D., Borowska, L., Unseld, A., et al. (2024) · Obesity · doi:10.1002/oby.24184 · Cited by 46
Self-citationWestermeier, F., & Fisman, E. Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02608-9 · Cited by 45
Epicardial Adipose Tissue and Heart Failure, Friend or Foe?
Cho, D., & Park, S. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0190 · Cited by 42
“A recent study demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RA) improved quality of life in patients with HFpEF and obesity [82].”
BackgroundSurvodutide for the Treatment of Obesity
Kosiborod, M., Platz, E., Wharton, S., le Roux, C. W., Brueckmann, M., Hussain, S. A., Unseld, A., Startseva, E., & Kaplan, L. M. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.09.004 · Cited by 42
Self-citationPacker, M., Zile, M. R., Kramer, C. M., DiMaria, J. M., Baum, S. J., Litwin, S. E., Murakami, M., Zhou, C., Ou, Y., Koeneman, L., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.06.058 · Cited by 34
Self-citationKommu, S., & Berg, R. L. (2024) · Obesity Reviews · doi:10.1111/obr.13792 · Cited by 50
“…data taken from the recently published large-scale RCTs, including the Semaglutide Treatment Effects in People with obesity-Heart Failure with preserved Ejection Fraction (STEP-HFpEF) 26 and the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) 27 trials.”
InfluentialObstructive Sleep Apnea, Obesity Hypoventilation Syndrome, and Pulmonary Hypertension
Bjork, S., Jain, D., Hache-Marliere, M., Predescu, S. A., & Mokhlesi, B. (2024) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2024.02.009 · Cited by 40
Settergren, C., Benson, L., Shahim, A., Dahlström, U., Thorvaldsen, T., Savarese, G., Lund, L. H., & Shahim, B. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3230 · Cited by 39
Karakasis, P., Vlachos, K. G., Antoniadis, A. P., Siontis, K. C., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156463 · Cited by 56
New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
Ryan, D. H. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09967-4 · Cited by 34
Myocardial Proteome in Human Heart Failure With Preserved Ejection Fraction
Jani, V., Yoo, E., Binek, A., Guo, A., Kim, J. S., Aguilan, J. T., Keykhaei, M., Jenkin, S. R., Sidoli, S., Sharma, K., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038945 · Cited by 58
“The recent GLP1-agonist semaglutide (STEP-HFpEF 43 ) improved symptoms and exercise capacity in HFpEF, and semaglutide has been found to increase mitochondrial protein expression in a mouse model of HFpEF.”
Self-citationNeves, J. S., Leite, A. R., Mentz, R. J., Holman, R. R., Zannad, F. M., Butler, J., Packer, M., & Ferreira, J. P. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3478 · Cited by 44
“4,5 A pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials showed that treatment with semaglutide reduced the risk of HF events, despite the low number of events in both trials.”
Self-citationNovel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 54
Myocardial Metabolism in Heart Failure with Preserved Ejection Fraction
Henry, J. A., Couch, L. S., & Rider, O. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051195 · Cited by 32
“The recently published STEP-HFpEF trial showed the benefit of the GLP1-RA semaglutide in inducing weight loss and improving symptoms in patients with HFpEF and obesity [106].”
BackgroundAlexiadou, K., Hartley, A., Tan, T. M.-M., & Khamis, R. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.03.003 · Cited by 31
Gogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2356254 · Cited by 32
“For people without diabetes, the mean WL with semaglutide 2.4 mg once weekly at 52 weeks was 13.3% (vs 2.6% WL with placebo, STEP HFpEF trial), when for people with T2D mean WL with semaglutide 2.4 mg was 9.8% (vs 3.6% WL with placebo, STEP HFpEF DM trial) [59,91].”
BackgroundMethodInfluentialSelf-citationLin, K., Ai, W., Zhai, C., Zhao, Y., Hu, H., Huang, D., Zhai, Q., Yan, Y., & Ge, J. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17327 · Cited by 39
“Semaglutide , a novel long-acting GLP-1RA, has demonstrated its favourable effects in the improvement of metabolic disorders and cardiovascular outcomes (Holman et al., 2017; Husain et al., 2019; Kosiborod et al., 2023; Wilding et al., 2021).”
GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196758 · Cited by 46
“The results showed that semaglutide improved symptoms (Kansas City Cardiomyopathy Questionnaire [KCCQ] score +16.6 points), physical function (6-minute walk distance +20 meters) and reduced body weight by 13% in obese patients with HFpEF, regardless of T2DM status [11].”
InfluentialThe cardiovascular effects of novel weight loss therapies
Usman, M., Davies, M. J., Hall, M. E., Verma, S., Anker, S. D., Rosenstock, J., & Butler, J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad664 · Cited by 31
Self-citationDani, S. S., Makwana, B., Khadke, S., Kumar, A., Jhund, P., Nasir, K., Sattar, N., Al-Kindi, S., Fonarow, G., Butler, J., et al. (2025) · JACC: Advances · doi:10.1016/j.jacadv.2025.101740 · Cited by 30
Self-citationMisrepresentation of semaglutide in social media
Propfe, L. E., & Seifert, R. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04403-5 · Cited by 54
Naser, J. A., Tada, A., Harada, T., Reddy, Y. N. V., Carter, R. E., Testani, J. M., Jensen, M. D., & Borlaug, B. A. (2024) · Circulation · doi:10.1161/circulationaha.124.069479 · Cited by 30
Self-citationAlkhouri, N., Charlton, M., Gray, M. E., & Noureddin, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473062 · Cited by 34
“The efficacy of once-weekly subcutaneous semaglutide 2.4 mg in individuals with HFpEF and obesity was recently assessed in the global Phase III STEP-HFpEF study [136].”
InfluentialObesity and Cardiovascular Disease: A New Dawn
Sattar, N. A., Neeland, I. J., & McGuire, D. K. (2024) · Circulation · doi:10.1161/circulationaha.123.065485 · Cited by 31
He, W., Wei, J., Liu, X., Zhang, Z., Huang, R., & Jiang, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-62465-6 · Cited by 30
“A recent study indicated that semaglutide led to larger reductions in symptoms and physical limitations, greater improvements in exercise function in patients with HFpEF and obesity 32 .”
BackgroundNakhla, M., Nair, A. V., Balani, P., Ujjawal, A., Kumar, P. A., Dasari, M., Yukselen, Z., Bansal, K., Ganatra, S., & Dani, S. S. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07613-w · Cited by 49
“Recent landmark trials, such as Sema-glutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF) [2] and Sema-glutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) [3], have established the cardio-protective benefits of these drugs even in the…”
Metadata
- Authors
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., Van der Meer, P., von Lewinski, D., Wolf, D., & Petrie, M. C.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) — all in the United Kingdom; the Department of Cardiovascular Medicine ...
- ORCID
- Kosiborod, Mikhail N.
- Borlaug, Barry A.
- Butler, Javed
- Davies, Melanie
- Hovingh, G. Kees
- Kitzman, Dalane W.
- Shah, Sanjiv J.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Merkely, Bela
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- Sharma, Kavita
- Wolf, Dennis
- Petrie, Mark C
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1069-1084
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4386154055
- Cited by
- 1,669
- References
- 41
- Citations by year
- 2026: 548 · 2025: 597 · 2024: 461 · 2023: 61
- FWCI
- 327.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, GLP-1 receptor agonists, heart failure events, body weight, symptom burden
- MeSH terms
- Semaglutide, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.